公开(公告)号：WO2008020666A1

公开(公告)日：2008-02-21

申请号：PCT/KR2006/005593

申请日：2006-12-20

申请人： SEOUL NATIONAL UNIVERSITY INDUSTRY FOUNDATION ,  LIM, Jeong Mook ,  HAN, Jae Yong ,  KIM, Hee Bal ,  LEE, Seoung Tae ,  LEE, Eun Ju ,  GONG, Seung Pyo

发明人： LIM, Jeong Mook ,  HAN, Jae Yong ,  KIM, Hee Bal ,  LEE, Seoung Tae ,  LEE, Eun Ju ,  GONG, Seung Pyo

IPC分类号： C12N5/08 ,  C12N5/06

CPC分类号： C12N5/0696 ,  C12N2501/235 ,  C12N2502/03 ,  C12N2502/04 ,  C12N2502/13 ,  C12N2502/1305 ,  C12N2502/1311 ,  C12N2502/1317 ,  C12N2502/1323 ,  C12N2502/1329 ,  C12N2502/1335 ,  C12N2502/1341 ,  C12N2502/1347 ,  C12N2502/1352 ,  C12N2502/1358 ,  C12N2502/1364 ,  C12N2502/137 ,  C12N2502/1376 ,  C12N2502/1382 ,  C12N2502/1388 ,  C12N2502/1394

摘要： The present invention relates to a method for preparing an embryonic stem cell (ESC)-like cell, which comprises the steps of: (a) obtaining a first cell population from a mammalian tissue or body fluid, wherein the first cell population comprises adult stem cells; (b) obtaining a second somatic cell population from a mammalian tissue, wherein the mammalian tissue is different from the mammalian tissue in step (a) and the second cell population is different from the first cell population; (c) coculturing the first cell population and the second cell population in a medium for a period of time sufficient to form a colony from either the first cell population or the second cell population; and (d) subculturing a cell from the colony in a medium for a period time sufficient to prepare the ESC-like cell.

摘要翻译： 本发明涉及一种用于制备胚胎干细胞（ESC）样细胞的方法，其包括以下步骤：（a）从哺乳动物组织或体液获得第一细胞群，其中所述第一细胞群包含成虫 细胞; （b）从哺乳动物组织获得第二体细胞群，其中所述哺乳动物组织在步骤（a）中不同于哺乳动物组织，而第二细胞群与第一细胞群不同; （c）在培养基中共培养第一细胞群体和第二细胞群体足以从第一细胞群体或第二细胞群体形成集落的时间; 和（d）在培养基中将细胞从菌落中传代培养足以制备ESC样细胞的时间。

公开(公告)号：WO2013124817A2

公开(公告)日：2013-08-29

申请号：PCT/IB2013051430

申请日：2013-02-21

申请人： BRAINSTEM BIOTEC LTD

发明人： BRODIE CHAYA ,  SLAVIN SHIMON

IPC分类号： C12N5/079

CPC分类号： A61K35/30 ,  A61K35/28 ,  A61K35/50 ,  A61K35/51 ,  C12N5/0622 ,  C12N15/113 ,  C12N2310/141 ,  C12N2320/11 ,  C12N2330/10 ,  C12N2501/01 ,  C12N2501/11 ,  C12N2501/115 ,  C12N2501/135 ,  C12N2501/195 ,  C12N2501/41 ,  C12N2501/65 ,  C12N2502/13 ,  C12N2502/1305 ,  C12N2502/1311 ,  C12N2502/1317 ,  C12N2502/1323 ,  C12N2502/1329 ,  C12N2502/1335 ,  C12N2502/1341 ,  C12N2502/1347 ,  C12N2502/1352 ,  C12N2502/1358 ,  C12N2502/1364 ,  C12N2502/137 ,  C12N2502/1376 ,  C12N2502/1382 ,  C12N2502/1388 ,  C12N2502/1394 ,  C12N2506/025 ,  C12N2506/1353 ,  C12N2506/1369 ,  C12N2506/1384 ,  C12N2506/1392 ,  C12N2510/00 ,  C12Q1/6876 ,  C12Q2600/178

摘要： A method of generating a population of cells useful for treating a nerve disease or disorder in a subject, the method comprising up-regulating a level of at least one exogenous mi RNA in mesenchymal stem cells (MSCs) and/or down-regulating a level of at least one mi RNA using a polynucleotide agent that hybridizes to the mi RNA, thereby generating the population of cells useful for treating the nerve disease or disorder. Isolated populations of cells generated thereby and uses thereof are also provided.

摘要翻译： 一种产生可用于治疗受试者的神经疾病或病症的细胞群的方法，所述方法包括上调间充质干细胞（MSC）中至少一种外源性mi RNA水平和/或下调水平 的至少一个mi RNA，使用与mi RNA杂交的多核苷酸试剂，从而产生可用于治疗神经疾病或病症的细胞群体。 还提供了由此产生的分离的细胞群和其用途。

公开(公告)号：WO2010051634A1

公开(公告)日：2010-05-14

申请号：PCT/CA2009/001601

申请日：2009-11-06

申请人： SUNNYBROOK HEALTH SCIENCES CENTRE ,  ZUNIGA-PFLÜCKER, Juan, Carlos ,  AWONG, Geneve ,  LA MOTTE-MOHS, Ross

发明人： ZUNIGA-PFLÜCKER, Juan, Carlos ,  AWONG, Geneve ,  LA MOTTE-MOHS, Ross

IPC分类号： C12N5/0783 ,  A61K35/14 ,  A61P31/18 ,  A61P35/00 ,  A61P37/06 ,  C12N5/10

CPC分类号： C12N5/0647 ,  A61K35/17 ,  A61K2035/124 ,  C12N5/0636 ,  C12N5/0646 ,  C12N5/0663 ,  C12N5/0669 ,  C12N2501/2302 ,  C12N2501/2307 ,  C12N2501/2315 ,  C12N2501/42 ,  C12N2502/13 ,  C12N2502/1305 ,  C12N2502/1311 ,  C12N2502/1317 ,  C12N2502/1323 ,  C12N2502/1329 ,  C12N2502/1335 ,  C12N2502/1341 ,  C12N2502/1347 ,  C12N2502/1352 ,  C12N2502/1358 ,  C12N2502/1364 ,  C12N2502/137 ,  C12N2502/1376 ,  C12N2502/1382 ,  C12N2502/1388 ,  C12N2502/1394 ,  C12N2502/99 ,  C12N2506/02 ,  C12N2506/11 ,  C12N2506/45 ,  G01N33/5005

摘要： Human progenitor T cells that are able to successfully engraft a murine thymus and differentiate into mature human T and NK cells are described. The human progenitor T cells have the phenotype CD34+CD7+CD 1a-CD5- or CD34+CD7+CD1a-CD5+ and are derived from human hematopoietic stem cells, embryonic stem cells and induced pluripotent stem cells by coculture with cells expressing a Notch receptor ligand (OP9-DL1 or OP9-DL4). Such cells are useful in a variety of applications including immune reconstitution, the treatment of immunodeficiencies and as carriers for genes used in gene therapy.

摘要翻译： 描述了能够成功移植鼠胸腺并分化成成熟的人T和NK细胞的人祖细胞T细胞。 人祖细胞T细胞具有表型CD34 + CD7 + CD 1a-CD5-或CD34 + CD7 + CD1a-CD5 +，并且通过与表达Notch受体的细胞共培养来源于人造血干细胞，胚胎干细胞和诱导的多能干细胞 配体（OP9-DL1或OP9-DL4）。 这样的细胞可用于各种应用，包括免疫重建，免疫缺陷的治疗和用于基因治疗的基因的载体。

公开(公告)号：WO2013158819A2

公开(公告)日：2013-10-24

申请号：PCT/US2013/037066

申请日：2013-04-18

申请人： ST. JUDE CHILDREN'S RESEARCH HOSPITAL

发明人： HAECKER, Hans

IPC分类号： C12N15/85

CPC分类号： C12N5/0647 ,  C12N5/0635 ,  C12N5/0636 ,  C12N5/0639 ,  C12N5/0642 ,  C12N5/0644 ,  C12N5/0645 ,  C12N2501/10 ,  C12N2501/125 ,  C12N2501/22 ,  C12N2501/2303 ,  C12N2501/2306 ,  C12N2501/26 ,  C12N2501/30 ,  C12N2501/60 ,  C12N2502/13 ,  C12N2502/1305 ,  C12N2502/1311 ,  C12N2502/1317 ,  C12N2502/1323 ,  C12N2502/1329 ,  C12N2502/1335 ,  C12N2502/1341 ,  C12N2502/1347 ,  C12N2502/1352 ,  C12N2502/1358 ,  C12N2502/1364 ,  C12N2502/137 ,  C12N2502/1376 ,  C12N2502/1382 ,  C12N2502/1388 ,  C12N2502/1394 ,  C12N2506/03 ,  C12N2510/00 ,  C12N2510/04

摘要： The present invention is a method and kits for generating a homogenous population of hematopoietic progenitor cells capable of differentiating into a hematopoietic cell lineage. Whereas the combination of Homeobox-B8 protein and FMS-like tyrosine kinase 3 ligand generate cells with the potential to differentiate into different myeloid and lymphoid cell types, Homeobox-A7 protein and erythropoietin generate cells with the potential to differentiate into erythropoietic or thrombopoietic cell types.

摘要翻译： 本发明是用于产生能够分化成造血细胞谱系的造血祖细胞的均匀群体的方法和试剂盒。 而Homeobox-B8蛋白和FMS样酪氨酸激酶3配体的组合产生具有分化成不同骨髓和淋巴细胞类型的潜力的细胞，Homeobox-A7蛋白和促红细胞生成素产生具有分化成红细胞生成或血小板生成细胞类型的潜力的细胞 。

公开(公告)号：WO2013105098A1

公开(公告)日：2013-07-18

申请号：PCT/IL2013/050035

申请日：2013-01-14

申请人： YEDA RESEARCH AND DEVELOPMENT CO. LTD.

发明人： ZIPORI, Dov ,  SHOSHANI, Ofer

IPC分类号： C12N5/071

CPC分类号： C12N5/0696 ,  C12N5/0663 ,  C12N13/00 ,  C12N2500/02 ,  C12N2502/13 ,  C12N2502/1305 ,  C12N2502/1311 ,  C12N2502/1317 ,  C12N2502/1323 ,  C12N2502/1329 ,  C12N2502/1335 ,  C12N2502/1341 ,  C12N2502/1347 ,  C12N2502/1352 ,  C12N2502/1358 ,  C12N2502/1364 ,  C12N2502/137 ,  C12N2502/1376 ,  C12N2502/1382 ,  C12N2502/1388 ,  C12N2502/1394 ,  C12N2506/1353 ,  C12N2510/00

摘要： The invention relates to induction of reprogramming of somatic cells, by methods which require mild growth conditions. Disclosed are methods of inducing dedifferentiation of mesenchymal stromal cell (MSC), by seeding or incubating mesenchymal stromal cells (MSCs) at low density, and without introduction or expression of exogenous genes in the cells.

摘要翻译： 本发明涉及通过需要温和生长条件的方法诱导体细胞重编程。 公开了通过以低密度接种或培养间充质基质细胞（MSC）诱导间充质基质细胞（MSC）去分化的方法，并且不在细胞中引入或表达外源基因。

公开(公告)号：WO2014184666A3

公开(公告)日：2015-01-22

申请号：PCT/IB2014001666

申请日：2014-04-30

申请人： UNIV LEUVEN KATH ,  ROOBROUCK VALERIE ,  DELFORGE MICHEL ,  VERFAILLIE CATHERINE M

发明人： ROOBROUCK VALERIE ,  DELFORGE MICHEL ,  VERFAILLIE CATHERINE M

IPC分类号： C12N5/074 ,  A01K67/027 ,  A61K35/54 ,  A61K49/00 ,  G01N33/50

CPC分类号： A61K35/545 ,  A61K49/0004 ,  C12N5/0607 ,  C12N2502/13 ,  C12N2502/1305 ,  C12N2502/1311 ,  C12N2502/1317 ,  C12N2502/1323 ,  C12N2502/1329 ,  C12N2502/1335 ,  C12N2502/1341 ,  C12N2502/1347 ,  C12N2502/1352 ,  C12N2502/1358 ,  C12N2502/1364 ,  C12N2502/137 ,  C12N2502/1376 ,  C12N2502/1382 ,  C12N2502/1388 ,  C12N2502/1394 ,  G01N33/5044

摘要： The invention provides methods for treating myelodysplasia syndrome (MDS). The invention is generally directed to reducing certain overt symptoms and disease-causing biological events in MDS by administering certain cells to a subject having MDS. The invention is also directed to drug discovery methods to screen for agents that modulate the ability of the cells to affect these events. The invention is also directed to cell banks that can be used to provide cells for administration to a subject, the banks comprising cells having desired potency for affecting these events.

摘要翻译： 本发明提供治疗骨髓增生异常综合征（MDS）的方法。 本发明一般涉及通过向具有MDS的受试者施用某些细胞来减少MDS中的某些明显症状和引起疾病的生物学事件。 本发明还涉及用于筛选调节细胞影响这些事件的能力的药剂的药物发现方法。 本发明还涉及可用于向受试者提供细胞的细胞库，所述细胞库包含具有影响这些事件的期望效力的细胞。

公开(公告)号：WO2014132032A1

公开(公告)日：2014-09-04

申请号：PCT/GB2014/050424

申请日：2014-02-13

申请人： CANCER RESEARCH TECHNOLOGY LIMITED

发明人： BONNET, Dominique ,  GRIESSINGER, Emmanuel

IPC分类号： C12N5/00 ,  C12N5/09 ,  C12N5/095

CPC分类号： C12N5/0694 ,  C12N2500/02 ,  C12N2501/145 ,  C12N2501/20 ,  C12N2501/22 ,  C12N2502/13 ,  C12N2502/1305 ,  C12N2502/1311 ,  C12N2502/1317 ,  C12N2502/1323 ,  C12N2502/1329 ,  C12N2502/1335 ,  C12N2502/1341 ,  C12N2502/1347 ,  C12N2502/1352 ,  C12N2502/1358 ,  C12N2502/1364 ,  C12N2502/137 ,  C12N2502/1376 ,  C12N2502/1382 ,  C12N2502/1388 ,  C12N2502/1394 ,  G01N33/5011 ,  G01N2800/52

摘要： The present invention relates to the in vitro and ex vivo culture of leukemia initiating cells (LICs). This has utility in various applications, such as screening for candidate agents for treating leukemia, identifying leukemia patients likely to respond to a candidate agent for treating leukemia, monitoring a leukemia patient for drug resistance, e.g. chemoresistance, to an agent, predicting the prognosis of a leukemia patient and determining the ability of a therapeutic agent to reduce the proportion of LICs in a leukemic patient.

摘要翻译： 本发明涉及白血病起始细胞（LIC）的体外和离体培养。 这在各种应用中具有实用性，例如筛选用于治疗白血病的候选药物，鉴定可能对候选药物进行白血病反应的白血病患者，监测白血病患者的耐药性，例如， 化学耐药性，预测白血病患者的预后并确定治疗剂降低白血病患者中LIC的比例的能力。

公开(公告)号：WO2013124817A3

公开(公告)日：2014-01-03

申请号：PCT/IB2013051430

申请日：2013-02-21

申请人： BRAINSTEM BIOTEC LTD ,  FORD HENRY HEALTH SYSTEM

发明人： BRODIE CHAYA ,  SLAVIN SHIMON

IPC分类号： C12N5/079 ,  A61P25/00 ,  A61P25/16 ,  C12N15/113

CPC分类号： A61K35/30 ,  A61K35/28 ,  A61K35/50 ,  A61K35/51 ,  C12N5/0622 ,  C12N15/113 ,  C12N2310/141 ,  C12N2320/11 ,  C12N2330/10 ,  C12N2501/01 ,  C12N2501/11 ,  C12N2501/115 ,  C12N2501/135 ,  C12N2501/195 ,  C12N2501/41 ,  C12N2501/65 ,  C12N2502/13 ,  C12N2502/1305 ,  C12N2502/1311 ,  C12N2502/1317 ,  C12N2502/1323 ,  C12N2502/1329 ,  C12N2502/1335 ,  C12N2502/1341 ,  C12N2502/1347 ,  C12N2502/1352 ,  C12N2502/1358 ,  C12N2502/1364 ,  C12N2502/137 ,  C12N2502/1376 ,  C12N2502/1382 ,  C12N2502/1388 ,  C12N2502/1394 ,  C12N2506/025 ,  C12N2506/1353 ,  C12N2506/1369 ,  C12N2506/1384 ,  C12N2506/1392 ,  C12N2510/00 ,  C12Q1/6876 ,  C12Q2600/178

摘要： A method of generating a population of cells useful for treating a nerve disease or disorder in a subject, the method comprising up-regulating a level of at least one exogenous miRNA in mesenchymal stem cells (MSCs) and/or down-regulating a level of at least one miRNA using a polynucleotide agent that hybridizes to the miRNA, thereby generating the population of cells useful for treating the nerve disease or disorder. Isolated populations of cells with an astrocytic phenotype generated thereby and uses thereof are also provided.

摘要翻译： 一种产生可用于治疗受试者神经疾病或病症的细胞群的方法，所述方法包括上调间充质干细胞（MSC）中至少一种外源miRNA的水平和/或下调 使用与miRNA杂交的多核苷酸试剂的至少一种miRNA，从而产生可用于治疗神经疾病或病症的细胞群。 还提供了由此产生的具有星形细胞表型的细胞的分离群体及其用途。

公开(公告)号：WO2013158819A3

公开(公告)日：2015-04-16

申请号：PCT/US2013037066

申请日：2013-04-18

申请人： ST JUDE CHILDRENS RES HOSPITAL

发明人： HAECKER HANS

IPC分类号： A01N63/00 ,  C12N5/071

CPC分类号： C12N5/0647 ,  C12N5/0635 ,  C12N5/0636 ,  C12N5/0639 ,  C12N5/0642 ,  C12N5/0644 ,  C12N5/0645 ,  C12N2501/10 ,  C12N2501/125 ,  C12N2501/22 ,  C12N2501/2303 ,  C12N2501/2306 ,  C12N2501/26 ,  C12N2501/30 ,  C12N2501/60 ,  C12N2502/13 ,  C12N2502/1305 ,  C12N2502/1311 ,  C12N2502/1317 ,  C12N2502/1323 ,  C12N2502/1329 ,  C12N2502/1335 ,  C12N2502/1341 ,  C12N2502/1347 ,  C12N2502/1352 ,  C12N2502/1358 ,  C12N2502/1364 ,  C12N2502/137 ,  C12N2502/1376 ,  C12N2502/1382 ,  C12N2502/1388 ,  C12N2502/1394 ,  C12N2506/03 ,  C12N2510/00 ,  C12N2510/04

摘要： The present invention is a method and kits for generating a homogenous population of hematopoietic progenitor cells capable of differentiating into a hematopoietic cell lineage. Whereas the combination of Homeobox-B8 protein and FMS-like tyrosine kinase 3 ligand generate cells with the potential to differentiate into different myeloid and lymphoid cell types, Homeobox-A7 protein and erythropoietin generate cells with the potential to differentiate into erythropoietic or thrombopoietic cell types.

摘要翻译： 本发明是用于产生能够分化成造血细胞谱系的造血祖细胞的均匀群体的方法和试剂盒。 而Homeobox-B8蛋白和FMS样酪氨酸激酶3配体的组合产生具有分化成不同骨髓和淋巴细胞类型的潜力的细胞，Homeobox-A7蛋白和促红细胞生成素产生具有分化成红细胞生成或血小板生成细胞类型的潜能的细胞 。

公开(公告)号：WO2014184666A2

公开(公告)日：2014-11-20

申请号：PCT/IB2014/001666

申请日：2014-04-30

申请人： KATHOLIEKE UNIVERSITEIT LEUVEN ,  ROOBROUCK, Valerie ,  DELFORGE, Michel ,  VERFAILLIE, Catherine, M.

发明人： ROOBROUCK, Valerie ,  DELFORGE, Michel ,  VERFAILLIE, Catherine, M.

IPC分类号： C12N5/00

CPC分类号： A61K35/545 ,  A61K49/0004 ,  C12N5/0607 ,  C12N2502/13 ,  C12N2502/1305 ,  C12N2502/1311 ,  C12N2502/1317 ,  C12N2502/1323 ,  C12N2502/1329 ,  C12N2502/1335 ,  C12N2502/1341 ,  C12N2502/1347 ,  C12N2502/1352 ,  C12N2502/1358 ,  C12N2502/1364 ,  C12N2502/137 ,  C12N2502/1376 ,  C12N2502/1382 ,  C12N2502/1388 ,  C12N2502/1394 ,  G01N33/5044

摘要： The invention provides methods for treating myelodysplasia syndrome (MDS). The invention is generally directed to reducing certain overt symptoms and disease-causing biological events in MDS by administering certain cells to a subject having MDS. The invention is also directed to drug discovery methods to screen for agents that modulate the ability of the cells to affect these events. The invention is also directed to cell banks that can be used to provide cells for administration to a subject, the banks comprising cells having desired potency for affecting these events.

摘要翻译： 本发明提供治疗骨髓增生异常综合征（MDS）的方法。 本发明一般涉及通过向具有MDS的受试者施用某些细胞来减少MDS中的某些明显症状和引起疾病的生物学事件。 本发明还涉及用于筛选调节细胞影响这些事件的能力的药剂的药物发现方法。 本发明还涉及可用于向受试者提供细胞的细胞库，所述细胞库包含具有影响这些事件的期望效力的细胞。